ArticleStem cell research & therapy2025
Comparative study of adipose tissue derived mesenchymal stem cells with rapamycin on paraquat-induced acute lung injury and pulmonary fibrosis in a mouse model: histological and biochemical study.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Organophosphate pesticide DEDT promotes diabetic retinopathy progression via AMPK/Nrf2/HO-1 pathway.Scientific reports · 2026Article
- Temporal dynamics of mesenchymal stem cell administration influence immune modulation in a 4T1 breast cancer model.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe most noticeable consequence of paraquat (PQ) toxicity is pulmonary fibrosis. Mesenchymal stem cells have the remarkable ability to self-renew and differentiate into many cell types. One such type is adipose tissue-derived Mesenchymal Stem Cells (AT-MSCs), which are derived from adipose tissue. Thus, the purpose of this study was to compare the effects of AT-MSCs and rapamycin on paraquat-induced acute lung injury and pulmonary fibrosis in a mouse model.
methodsFifty female mice were randomly allocated to four groups. Group I (control group) received the drug solvent using the same route of administration for the same duration as the corresponding experimental groups. Group II (pulmonary fibrosis group) lung injury was induced by injection of PQ at a dosage of 40 mg/kg. Group III (AT-MSCs group) received 1.0 × 10
resultsFollowing injection with AT-MSCs, there was an increase in Y-chromosome expression levels. Treatment with AT-MSCs also reduced malondialdehyde levels in the lung tissues while increasing superoxide dismutase and reduced glutathione levels. The results showed that pulmonary fibrosis may be mitigated following AT-MSCs transplantation in PQ-poisoned mice by suppressing the synthesis of pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-alpha) in the lung tissues of the animals. The SRY gene's expression was significantly upregulated in the AT-MSCs treatment group.
conclusionThis study provides more evidence that the immunomodulatory effects of AT-MSC transplantation can alleviate pulmonary inflammatory and fibrotic alterations more effectively than rapamycin. As a result, these cells are a very promising pharmacological therapy for acute lung injury and pulmonary fibrosis induced by PQ poisoning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.